Survey Monocef-OCV/CSOM/26-27MCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File 1. What is the most common challenge you face when treating acute exacerbations of CSOM in your clinical practice? High rates of patient non-compliance with TID (three times daily) dosing Increasing resistance to conventional Beta-lactam monotherapy Difficulty in achieving therapeutic concentrations in the middle ear Frequent recurrence of discharge post-treatment2. How frequently do you encounter Beta-lactamase-producing organisms (e.g., S. aureus, H. influenzae) in ear swab cultures from CSOM patients? Rarely (Less than10%) Occasionally (10-30%) Frequently (30-60%) Very Frequently (More than 60%)3. In the context of "Switch Therapy" (from IV to Oral), which oral antibiotic profile do you prioritize for maintaining clinical efficacy in CSOM? Broad-spectrum coverage including Gram-positive and Gram-negative pathogens Stability against Beta-lactamase degradation High bioavailability and middle ear tissue penetration All of the above4. How do you rate the importance of Clavulanic Acid in an oral regimen to overcome bacterial resistance during an acute exacerbation? Critical - Essential to protect the primary antibiotic from enzymatic degradation Moderate - Useful only in confirmed resistant cases Minimal - Prefer using higher doses of monotherapy Uncertain5. What is your preferred oral Cephalosporin for treating respiratory and ENT infections due to its superior pharmacokinetic profile and BID (twice daily) convenience? Cefixime Cefpodoxime Proxetil Cefadroxil Cephalexin6. Cefpodoxime Proxetil is a third-generation cephalosporin. How does its expanded Gram-negative coverage influence your choice in CSOM management? Significant Moderate Low It is my first-line choice for empirical therapy7. When treating acute exacerbations, how does a Cefpodoxime (200mg) + Clavulanic Acid (125mg) combination compare to Cefixime + Clavulanic Acid in your experience? Cefpodoxime combo offers better tissue penetration and clinical cure rates Both are identical in efficacy Cefixime is preferred despite lower tissue concentration Cefpodoxime combo shows better GI tolerability in my patients8. To what extent does a BID (Twice Daily) dosage regimen (like Cefpodoxime + Clavulanic Acid) improve patient adherence compared to TID regimens in the Indian demographic? Significantly improves compliance and treatment success Marginally improves compliance No noticeable difference Patients prefer QD (Once Daily) regardless of efficacy9. In your clinical observation, what is the typical timeline for the resolution of otorrhea (ear discharge) when using a Cefpodoxime + Clavulanic Acid combination? Rapid resolution (within 3–5 days) Moderate resolution (5–7 days) Slow resolution (More than 7 days) Requires supplemental topical therapy in all cases10. Would you consider the combination of Cefpodoxime 200mg and Clavulanic Acid 125mg as a "gold standard" oral empirical therapy for acute exacerbations of CSOM to prevent intracranial/extracranial complications? Yes, it provides the necessary spectrum and resistance coverage Yes, primarily due to the potent Beta-lactamase inhibition It is a second-line option for me Only for paediatric cases I have read and agree to the Terms and Conditions .Submit Form